A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Description

This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.

Conditions

Metastatic Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.

Phase II Study to Examine Precision Radiation in Patients With Pathogenic Mutations in ATM

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Condition
Metastatic Cancer
Intervention / Treatment

-

Contacts and Locations

Basking Ridge

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States, 10065

Middletown

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States, 07645

Commack

Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States, 10065

Uniondale

Memorial Sloan Kettering Nassau (All protocol activities), Uniondale, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy
  • * Pathogenic mutation in ATM (somatic and germline allowed)
  • * ECOG performance status 0-2
  • * Age ≥ 18 years.
  • * Able to provide informed consent.
  • * Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments.
  • * Expected life expectancy of at least 6 months
  • * Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
  • * Serious medical co-morbidities precluding radiotherapy.
  • * Pregnant or breast-feeding women.
  • * Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Amy Xu, MD, PhD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2026-08